Clinical Trial Update: Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting safety and immunogenicity of a recombinant protein RBD fusion dimer vaccine targeting SARS-CoV-2 for COVID-19.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sars-cov-2 Acute Respiratory Disease

Drugs mentioned

• RBD Fusion Dimer Vaccine (recombinant protein)

Snippet

Sponsor: Hipra Scientific, S.L.U | Conditions: COVID-19, SARS-CoV-2 Acute Respiratory Disease | Phase 2 | Status: COMPLETED